However, our panel included additional conditions such as tyrosinemias (TYR1–3), other fatty acid oxidation disorders (e.g., VLCAD, SCAD, PCD), and further subtypes of galactosemia (GALK deficiency), which likely contribute to the higher total number of screened disorders. This evidence concerns the gene GALK1 and very long chain acyl-CoA dehydrogenase deficiency.